Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

Pharmacology, Toxicology and Pharmaceutical Science

• Hyperlipidemia 100%
• Oxidoreductase 100%
• Atorvastatin 100%
• Human Immunodeficiency Virus Proteinase Inhibitor 100%
• HMG-CoA 100%
• Pravastatin 75%
• Proteinase Inhibitor 75%
• Statin (Protein) 50%
• HIV 50%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 25%
• Human Immunodeficiency Virus Infection 25%
• Fibric Acid Derivative 25%
• Pancreatitis 25%
• Ischemic Heart Disease 25%
• Drug Interaction 25%
• Triacylglycerol 25%
• Low Density Lipoprotein 25%
• Hepatotoxicity 25%
• Rhabdomyolysis 25%
• Cardiovascular Disease 25%

Keyphrases

• Atorvastatin 100%
• HIV Protease Inhibitors 100%
• 3-hydroxy-3-methylglutaryl-coenzyme A 100%
• Risk-benefit 100%
• Reductase Inhibitors 100%
• Statins 42%
• Protease Inhibitors 42%
• HIV Patients 28%
• Drug Interactions 14%
• Coronary Artery Disease 14%
• Cardiovascular Risk 14%
• HIV Infection 14%
• Quality of Life 14%
• Toxicity Issues 14%
• Cholesterol Levels 14%
• Pancreatitis 14%
• Triglyceride Level 14%
• Serum Lipids 14%
• National Cholesterol Education Program 14%
• Low-density Lipoprotein 14%
• Hepatotoxicity 14%
• Number of Patients 14%
• Maximum Tolerated Dose 14%
• Starting Dose 14%
• Low Cholesterol 14%
• Myotoxicity 14%
• Acceptable Risk 14%
• Second-line Agents 14%
• Risk-benefit Ratio 14%
• Rhabdomyolysis 14%
• Fibrates 14%